On 17 October 2019, orphan designation EU/3/19/2213 was granted by the European Commission to Ascendis Pharma Endocrinology Division A/S, Denmark, for lonapegsomatropin for the treatment of growth hormone deficiency.
|Disease / condition||
Treatment of growth hormone deficiency
|Date of first decision||
|EU designation number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: